-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Kura Oncology, Lowers Price Target to $15

Benzinga·03/13/2026 20:27:26
Listen to the news
UBS analyst David Dai maintains Kura Oncology (NASDAQ:KURA) with a Buy and lowers the price target from $16 to $15.